From the total control pool, we determined 74 subjects without any traditional risk factors (less than 60 years old, diabetes mellitus, hypertension, hyperlipidemia, smoking, sedentary life, obesity) or any disease or treatment. From this cohort, 23 subjects could be exactly matched for age and sex with 23 AL patients and their matched counterparts for risk factors, using the same method as described above.
Methods

Controls' selection in the prospective cohort
In order to assess differences in vascular characteristics attributed to the disease, AL patients were matched to controls in a 1:k (maximum k=7) ratio by using a greedy matching algorithm of nearest neighbor for age and sex 1 . Sex was matched exactly whilst the caliper for age enabled matching within a range of 2 years. Next, renal dysfunction by eGFR-staging (CKD Stage I >90, Stage II 60-90, Stage IIIA 45-60, Stage IIIB 30-45, Stage IV 29-15 and Stage V <15 ml/min/1.73m2) was determined within cases and k-control pairs. All eligible controls with the same CKD stage were retained and evaluated in the next matching steps that employed a relevant iterative approach for the following exposure variables in hierarchical order: CAD, diabetes mellitus, smoking and hyperlipidemia. If no matching could be achieved on CKD stage (as well as on subsequent matching factors) for neither of k controls, we retained these pairs and evaluated sequentially the next matching criteria (CAD, DM, smoking and hyperlipidemia). Hypertension was not a matching criterion because low BP is a clinical characteristic of AL, which was part of the main hypothesis of the study. At the final step, if more than one matches for all parameters were available, one was selected at random to remove any potential bias.
Controls were retrospectively recruited from an ongoing FMD registry of subjects examined in our laboratory between 2008-2018 for research purposes. The FMD registry is currently comprised of 5 cohorts as follows 1. patients at high CV risk (n=213), 2. Volunteers at low or moderate risk (n=204) 3 . Patients with various levels of renal dysfunction (n=47) 4. Postmenopausal women (n=571) and 5.
Young healthy volunteers with ideal CV risk profile (n=36). FMD registry cohorts have been recruited for the purposes of previously published and ongoing clinical research (example publications: [2] [3] [4] [5] [6] [7] [8] [9] ). FMD in this registry was performed in the same laboratory using the same FMD protocol and analyzed by the same operator (MK).
In all participants, a complete documentation of history, clinical and biochemical parameters for the presence of traditional risk factors (diabetes, smoking, dyslipidemia and hypertension), coronary artery disease and renal function was obtained. Renal function and staging was evaluated based on eGFR, calculated by the MDRD formula 10 . Renal function staging was based on standard guidelines.
Hypertension was defined as reported history of hypertension or antihypertensive treatment before diagnosis of AL amyloidosis or office SBP >140 and/or DBP>90mmHg on two different occasions.
Dyslipidemia was defined as reported history of hyperlipidemia or hypolipidemic treatment or total cholesterol >200mg/dl. Diabetes was defined as reported history of diabetes or antidiabetic treatment or fasting plasma glucose >126mg/dl on 2 occasions or diagnostic postprandial glycemic curve.
Orthostatic hypotension (or postural hypotension) was defined as a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within 3 minutes of standing 11 .
Mayo Staging in AL patients
We classified AL patients (prospective derivation and validation cohort) into groups of disease prognosis and therapeutic response by using the widely staging system of Mayo Clinic 2004. We used the following combinations of NT-proBNP and cardiac TnT or TnI at presentation of diagnosis: stage I (NT-proBNP <332 ng/L and troponin-T <0.035 μg/L), stage II (NT-proBNP >332 ng/L or troponin-T >0.035 μg/L), stage IIIA (NT-proBNP >332 ng/L and troponin-T >0.035 μg/L) and stage IIIB (NT-proBNP >8500 ng/L and troponin-T >0.035 μg/L) 12, 13 . A stage IIIB subgroup is associated with poorest survival 14 .
Vascular studies
During initial evaluation visit and before initiation of any chemotherapy or steroids, a series of vascular studies were performed. Peripheral vascular studies were performed in all patients and controls as previously described 2, 7, 15 . All subjects abstained from food or drink or smoking at least 12 hours before vascular studies. Vaso-active medication, including antihypertensive and hypolipidemic treatment, was retained for at least 2 drug half-lives prior to vascular measurements. Reactive vasodilatory was assessed by flow-mediated vasodilation (FMD). FMD was measured using high resolution ultrasonography (14.0-MHz multifrequency linear array probe, Vivid 7 Pro; General Electric Healthcare, Milwaukee, Wisconsin, USA). FMD was measured in the right brachial artery of each subject offline on ECG R wave by acquiring an average of 3 diameter measurements at baseline and the maximum diameter from a series of continuous manual measurements taken every 15 seconds after cuff deflation (post to 5 minutes ischemic inflation at the level of antebrachium) for a time period of 90 seconds 16 . The intraobserver variability for brachial artery diameter measurements in our laboratory was 0.08 ± 0.19 mm, and intraclass correlation coefficient (ICC) for 2 repeated measurements of FMD at 2 consecutive days was 0.743. We normalized brachial artery diameter to body surface index (brachial artery diameter in mm/ body surface index in m 2 ) as previously described 17 . A dedicated automatic border detection software (Medical Imaging Applications LLC, USA) was made available after initiation of the study 18 . However, given a. the prospective nature of the study, b. the rarity and high early mortality of the disease under study and c. in order to retain as high as possible dataset consistency, we chose not to exclude the manually measured FMD measurements until that point but rather to complete FMD analyses in all subjects as initially designed. In a subgroup of 23 AL patients and 35 controls, FMD was calculated and compared using both methods. The level of agreement between the 2 methods based on the ICC calculation was satisfactory (ICC=0.881).
In a secondary approach, FMD was allometrically scaled to baseline diameter of right brachial artery as previously described 19 . In brief, we used a log-linked generalized linear model with the change in diameter as the outcome and logarithmically transformed baseline diameter of right brachial artery as a covariate and obtained percentage values of allometric FMD by dividing the covariate-adjusted mean difference with the antilog value of the coefficient of baseline diameter.
Rationale for not measuring nitrate induced dilation
Nitrate induced dilation (NID) was not measured in this study in order to avoid serious nitroglycerin induced reactions in this group of patients with high prevalence of symptomatic (32.2%) hypotension.
Most importantly, as explained below, other conditions such as autonomic and cardiac dysfunction, commonly found in AL amyloidosis, may mediate serious adverse effects of nitroglycerin. Thus, we decided to avoid nitroglycerin administration because we could not exclude unpredictable severe reactions in some patients from the AL population.
In specific, acute administration of nitroglycerin: a. may induce an unpredictable syndrome of hypotension and bradycardia 20, 21 , b . may induce inhibition of sympathetic system through triggering of alpha 2-adrenoceptors as a consequence of stimulation of peripheral sensory receptors with vagal afferents to the medulla 22 and c. may provoke prolonged post-faint hypotension at least partly through lowering of cardiac output 23 .
Given that the main reasons for hypotension in AL amyloidosis are believed to be low cardiac output, low oncotic pressure due to hypoalbuminemia and mainly autonomic dysfunction manifested as vascular sympathetic denervation and a generalized dysfunction in the autonomic control of vascular reactivity 24 , these adverse actions of nitroglycerin on AL patients may jointly and unpredictably exacerbate most of the hypotensive effects with possible severe presentation and even life threatening bradycardic arrhythmias. In support, a recent study indicated that most AL patients with cardiac amyloidosis die due to bradycardic arrhythmias 25 . Considering this evidence, we deemed that we would not be able to accurately predict an acute exacerbation of severe and possibly life-threatening hypotensive and/or bradycardic reaction by nitroglycerin-induced autonomic dysfunction in this specific group by simply excluding those with hypotension. Indeed, in our population most of AL patients had cardiac involvement with cardiac dysfunction (67%) and signs of autonomic dysfunction (40%) reflected by orthostatic hypotension and/or peripheral nerve involvement.
We discarded the option to measure NID in the rest of the patients who did not have cardiac or autonomic dysfunction because 1. this would introduce major selection bias 2. the sample size would be too small (n=32, 27.8%) and would not be representative of the population and 3. safety could not be guaranteed given that these reactions are often unpredictable.
Ultrasound was performed in the carotid and femoral arteries using a 14.0 MHz multi-frequency linear array probe attached to a high-resolution ultrasound machine (14.0-MHz multifrequency linear array probe, Vivid 7 Pro; General Electric Healthcare, Milwaukee, Wisconsin, USA) 15, 26, 27 . Carotid segments of interest are described as follows: a. right and left common carotid artery, defined as the segment 1 cm proximal to carotid dilation, b. carotid bulb, defined as the segment between the carotid dilation and carotid flow divider and c. internal carotid artery, defined as 1 cm long arterial segment distal to the flow divider. In each arterial segment of interest, the maximal intima-media thickness (IMT) in the far wall was obtained offline, gated at R-wave, using a dedicated automated border detection software (GE Healthcare). Carotid IMT IOCV ranged between 4 and 10%, depending on the segment. All measurements were obtained by an experienced operator blinded to the medical history of the patients. Carotid and/or femoral plaques were recorded after detailed interrogation of each segment of interest to identify the optimal image showing maximum plaque size with the greatest encroachment into the lumen. Plaques were defined as a focal structure that encroaches into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value or demonstrates a thickness of ≥1.5 mm.
Shear stress calculation
Hyperemic shear stress is a major correlate of brachial artery flow-mediated dilation 28 . We calculated shear rate as an approximation of shear stress 29 averaged over the whole cardiac cycle by using the equation: Shear stress (in dyn/cm2)= 8 × μ × mean flow velocity/resting diameter, where μ is the viscosity of blood as previously described 30 . Blood viscosity, μ was assumed to be 0.035 dyne×s/cm 2 .
Rationale and description for additional assessment of possible mechanisms associated with increased FMD in AL amyloidosis
Given the difference in FMD between AL patients and controls and the association of its increased values with all-cause mortality, we sought to provide mechanistic insights on the paradoxically increased reactive vasodilatation in this special group of interest.
In specific, we addressed 2 hypotheses: 1. That autonomic dysfunction affecting vascular function, which is commonly found in AL amyloidosis, would be associated with increased FMD. In specific we hypothesized that due to commonly found impaired sympathetic vascular modulation in AL amyloidosis 24 , any vasoconstrictive response to sympathetic stimulation would be attenuated. FMD is known to be augmented in conditions of sympathetic attenuation [31] [32] [33] [34] [35] . For this purpose, we performed cold pressor test (CPT) in a population of AL patients and healthy control subjects without amyloidosis and assessed brachial arterial changes during and after this well validated sympathetic stimulus [36] [37] [38] [39] 
2. Since FMD is known to be at least partly mediated by nitric oxide (NO) availability, we measured markers of the metabolic pathways in our population of AL patients and controls. In specific, we hypothesized that markers of NO bioavailability and associated nitrosative stress would be augmented in AL patients as compared to their controls. To this end, we measured exhaled alveolar NO and circulating levels of nitrites as indirect measurement of NO availability [40] [41] [42] , cGMP as the target molecule of NO in tissues 40, 42, 43 and 3-nitrotyrosine as an index of nitrosative stress 44 .
Cold pressure test
Nineteen newly recruited AL patients and 10 healthy volunteers underwent brachial artery diameter assessment during and after concomitant sympathetic stimulation. Online Table VIII outlines diseasespecific characteristics of AL patients (n=19).
For stimulation of the sympathetic nervous system, immersion of left hand in iced water (4 o C) was used 36, 45 . All measurements were performed in a quiet, temperature-controlled room. The hand remained in iced water for 3 minutes (Cold pressure test, CPT). Responses to CPT were analyzed as following: A pre-CPT diameter of right brachial artery was determined from the average 60 s data prior to placing of the subject's hand in ice water. Subsequently, brachial artery diameter was analyzed a) during the 3 mins of CPT and b) for additional 3 minutes following removal of patient's hand from ice water 46 . The minimal, mean and maximal right brachial diameter and CPT response were recorded as a percent change from the pre-CPT base diameter. High resolution ultrasonography (14.0-MHz multifrequency linear array probe, Vivid 7 Pro; General Electric Healthcare, Milwaukee, Wisconsin, USA) and automatic border detection software (Medical Imaging Applications LLC, USA) was implemented for CPT in all subjects. Noradrenaline was measured at three pre-specified time points in all participants, at the baseline, 2 minutes post application of the cold stimulus and 15 minutes after removal of the cold stimulus 47 . At these time points, plasma samples were collected using EDTA-Na2 as an anticoagulant. The samples were centrifuged for 15 minutes at 1000×g at 4°C within 30 minutes of collection. The supernatant was collected and stored at -80 o C for the analysis of noradrenaline using a commercially available kit (Noradrenaline Research ELISA, BA E-5200, Rocky Mountain Diagnostics, Inc.) Briefly, 400μL of plasma samples and diluted standards and controls were placed in a cis-diol-specific affinity gel plate for the extraction of noradrenaline. Then, noradrenaline was acetylated and converted enzymatically according to manufacturer's instructions.
The derivatized standards, controls and samples were assigned to the competitive ELISA microtiter plate format and quantification of noradrenaline in the samples was achieved by comparing their absorbance with the standard curve using Graph Pad prism version 7 (Graph Pad Software, Inc.) (assay sensitivity 2pg/mL), The results were expressed in nmol/mL.
Nitric oxide pathway
In a subgroup of AL (n=57) and control patients (n=24) with available blood plasma samples, we measured markers of the NO metabolic pathway. In specific, we quantified circulating levels of nitrites as indices of NO availability 41 , cGMP as the target molecule of NO in tissues 40, 42, 43 and 3nitrotyrosine an index of nitrosative stress 44 . In addition, we measured exhaled alveolar NO in a newly recruited group of AL patients (n=26) as compared to a healthy control group without AL (n=30).
Descriptive characteristics of the subgroup of AL patients, as well as comparisons with the overall AL population, are depicted in online Tables IX-XI.
Blood measurements
In the subgroup of AL (n=57) and control patients (n=24) plasma samples were collected using EDTA-Na2 as an anticoagulant. The samples were centrifuged for 15 minutes at 1000×g at 4°C within 30 minutes of collection. The supernatant was collected and stored at -80 o C for further analysis. Each sample was assigned a unique identification code and the researcher who performed the blood measurements was blinded.
Circulating nitrite measurement
The concentration of nitrite in blood plasma was determined using Griess reaction with a commercially available kit (Cayman's Nitrate/Nitrite Colorimetric Assay Kit 780001) as we have described previously 48 . Each plasma sample was ultrafiltered through a 10kDa molecular weight cutoff filter (Pall Nanosep® centrifugal device with Omega membrane, Sigma Aldrich: Z722065). The filters were pre-rinsed with Ultrapure water prior to ultrafiltration of the plasma. Then, 500μL of plasma was centrifuged for 30 minutes at 14.000xg at 4 ο C. For the determination of nitrites, 40μL of the filtrate was used, the Griess reagents were added and the absorbance of each well was measured at 540nm using the reader Infinite 200 PRO series (Tecan). The concentration of nitrite was determined with a nitrite standard curve using Graph Pad prism version 7 (Graph Pad Software, Inc.) according to the manufacturer's instructions. The results were expressed in μmol/L and converted to log scale prior to statistical analysis.
Plasma cyclic GMP levels determination
The cGMP content was determined using a commercially available enzyme-linked immunosorbent assay kit following the manufacturer's instructions (Direct cGMP ELISA kit, Enzo Life Sciences:
ADI-900-013) as we have previously described 49 The whole population refrained from eating, drinking and smoking before NO analysis, did not suffer from respiratory infections and did not receive inhaled or oral corticosteroids 53 .
Statistical analysis
Continuous variables are expressed as mean±standard deviation for variables following normal Differences between controls and cases were assessed by independent samples T-Test for continuous variables and chi-square test for nominal variables. When more than 2 groups were compared for continuous variables, we used one-way Analysis of Variance (ANOVA) with post-hoc comparisons corrected by the Dunnett's method. FMD did not follow the normal distribution in histograms and quantile-quantile plots and was tested after natural log transformation or inverse rank normalization.
For the main outcome (i.e. FMD in logarithmic scale), we used linear regression analysis to further compare the two groups after adjusting for potential confounders: a) traditional risk factors, i.e. systolic and diastolic BP, hypertension, hyperlipidemia, smoking and diabetes mellitus b) baseline brachial artery diameter and post-occlusion hyperemic flow stimulus c) presence of peripheral plaque and/or coronary artery disease. In a second/confirmatory step, continuous FMD was used as the dependent variable after inverse ranking normalization. For each added confounder, we calculated a) the increase in the adjusted R squared index as an estimate of explained variation and b) we employed a cross validation procedure (leave one observation in an iterative approach) to calculate the predicted adjusted R squared index after fitting the multivariable model in differing data sets and compared observed to predicted R squared index; to avoid overfitting of the multivariable linear regression model, the three sets of confounders (a-c), were sequentially tested. We did not found evidence of collinearity among the confounders by using the variance inflation factor. We used residual analysis to test for goodness of fit οf the multivariable regression models. Certain variables with extremely skewed distribution such as NTproBNP and hsTnT were compared between independent samples by the non-parametric Mann Whitney U test. Finally, we assessed the possible difference in changes of noradrenaline levels during the CPT test between AL patients and healthy controls by employing a two-level linear mixed model with random intercept and random slope; noradrenaline was transformed with the natural logarithm and was used as the dependent variable whereas the disease status (i.e. healthy control or AL patient) was inserted as an independent factor. Moreover, we assessed the possible difference in changes of noradrenaline levels during the CPT test between AL patients and healthy controls by employing a two-level linear mixed model with random intercept and random slope; noradrenaline was transformed with the natural logarithm and was used as the dependent variable whereas the disease status (i.e. healthy control or AL patient) was inserted as an independent factor. Finally, in the FMD registry (n=1,071), we used multivariable linear regression analysis to derive independent determinants of FMD. A pre-specified set of exposure variables was included in the model, i.e. age, sex, hypertension, hyperlipidemia, diabetes mellitus, eGFR stage and CAD.
Analysis of the prospective survival data
Cox proportional-hazards models were used to examine the association between baseline predictors and main endpoints of our study; data were censored at the time of the last visit. For patients lost during follow-up, their survival data were censored at the last date they were known to be alive. All cause death was flagged as the primary endpoint in survival analysis. Early mortality at 6 months was assessed as a secondary endpoint. The proportional hazard assumption of Cox model was assessed using the appropriate graph and statistical test (Schoenfeld residuals). Associations are presented as Hazard Ratio (HR) with 95% confidence intervals (CI). Multivariable survival models (i.e. best predictive model) for main endpoints were built as previously described 14 : After reviewing potential prognostic variables of overall survival in AL amyloidosis from well-designed studies with adequate sample size and complete phenotyping 14 , we tested all proposed predictors in univariate Cox regression models. We did not apply exclusion criteria in terms of prognostic variables; thus, variables that were not shown previously to affect prognosis but were biologically plausible (e.g. age and sex) were tested as well under univariate settings. Those presenting a signal or significant association (p<0.1) in univariate models were tested in the multivariable Cox models to identify independent parameters for survival endpoints. Predictors that were tested in univariate models were age, sex, Mayo Stage, renal-, liver-and nerve involvement, levels of dFLC, SBP≤100 mmHg, SBP as continuous variable, FMD<or ≥4.5%, CAD and presence of atherosclerotic plaque. Three multivariable models were used: a) Mayo Stage, nerve involvement, SBP≤100 mmHg and FMD<or ≥4.5% b) model A plus shear stress, baseline brachial diameter and hyperemic flow and c) model A plus age, sex, presence of coronary artery disease and presence of subclinical atherosclerosis. The interaction between FMD subgroups and potential effect modifiers in association with the endpoint of interest was statistically tested by introducing interaction-terms into the Cox regression models, and none of them were found to be statistically significant at P< 0.05 level.
In order to investigate the potential non-linear association between the continuous FMD and all-cause mortality in AL patients (n=115), we implemented restricted cubic splines (RCS) (i.e. natural splines) with 3 knots fixed at the 10th, 50th and 90th percentile of the FMD distribution and produced a smooth curve versus logHR in the y axis 55 . Selection of the number of knots was data-driven. In specific, we fitted models with different number of knots in a non-parsimonious approach and compared the Bayesian information criterion (BIC); among models with different number of knots, the one with smaller BIC was selected. In case of trivial differences in BIC, we favored less complex models (3 knots:406.1, 4 knots: 405.5 and 5 knots: 410.1, respectively). In contrast, knot placement was prespecified according to fixed percentiles of FMD's marginal distribution, given that there was no prior knowledge in literature of possible change points. However, knots' placement is not as crucial as their number for adequate fit to observed data [56] [57] [58] [59] . Cox regression models with FMD modeled as a continuous term or in the form of RCS were compared in terms of information criteria (AIC, Akaike's information criterion). the log-rank test and estimates the value of a continuous predictor that maximizes the difference in survival between the two groups defined by the optimal cutoff point. We further confirmed the existence of the cut off point for FMD by ROC analysis and selection of the maximum product of sensitivity and specificity (Liu method) 61 , which indicated the FMD cutoff value best predicting mortality among AL amyloidosis patients.
After visual inspection of the dose-response curve between all-cause mortality and FMD that
In addition, we sought to assess the incremental value of FMD over established risk factors in terms of reclassification improvement for the pre-specified endpoint by implementing the continuous NRI (NRI), a category-free version of the NRI 62 , and the integrated discrimination improvement (IDI), which integrates the NRI over all possible cutoffs and is equivalent to the difference in discrimination slopes (all measures of reclassification) 62 . Correct reclassification was defined as new risk estimates for all-cause death showing increased concordance to actual mortality, i.e. higher risk for AL patients who eventually died and lower risk for participants who survived until the end of the follow-up period by adding increased FMD over the core prognostic model.
Sample size calculations
In terms of survival analysis, the final sample size of 115 subjects and 48 events provided over 85% power to establish a 2.5-fold alteration in HR (two-sided) towards the primary endpoint, assuming a ratio of control to experimental group of 1. 35 corrected by the Holm-Bonferroni method 63 to control the family-wise error rate. We deemed statistical significance at a=0.05.
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